Abstract Mycophenolic acid (MPA) is a potent immunosuppressant agent, which is increasingly being used in the treatment of patients with various autoimmune diseases. Dosing to achieve a specific target MPA area under the concentration-time curve from 0 to 12 h post-dose (AUC 12 ) is likely to lead to better treatment outcomes in patients with autoimmune disease than a standard fixeddose strategy. This review summarizes the available published data around concentration monitoring strategies for MPA in patients with autoimmune disease and examines the accuracy and precision of methods reported to date using limited concentration-time points to estimate MPA AUC 12 . A total of 13 studies were identified that assessed the correlation between single time points and MPA AUC 12 and/or examined the predictive performance of limited sampling strategies in estimating MPA AUC 12 . The majority of studies investigated mycophenolate mofetil (MMF) rather than the enteric-coated mycophenolate sodium (EC-MPS) formulation of MPA. Correlations between MPA trough concentrations and MPA AUC 12 estimated by full concentration-time profiling ranged from 0.13 to 0.94 across ten studies, with the highest associations (r 2 = 0.90-0.94) observed in lupus nephritis patients. Correlations were generally higher in autoimmune disease patients compared with renal allograft recipients and higher after MMF compared with EC-MPS intake. Four studies investigated use of a limited sampling strategy to predict MPA AUC 12 determined by full concentration-time profiling. Three studies used a limited sampling strategy consisting of a maximum combination of three sampling time points with the latest sample drawn 3-6 h after MMF intake, whereas the remaining study tested all combinations of sampling times. MPA AUC 12 was best predicted when three samples were taken at pre-dose and at 1 and 3 h postdose with a mean bias and imprecision of 0.8 and 22.6 % for multiple linear regression analysis and of -5.5 and 23.0 % for maximum a posteriori (MAP) Bayesian analysis. Although mean bias was less when data were analysed using multiple linear regression, MAP Bayesian analysis is preferable because of its flexibility with respect to sample timing. Estimation of MPA AUC 12 following EC-MPS administration using a limited sampling strategy with samples drawn within 3 h post-dose resulted in biased and imprecise results, likely due to a longer time to reach a peak MPA concentration (t max ) with this formulation and more variable pharmacokinetic profiles. Inclusion of later sampling time points that capture enterohepatic recirculation and t max improved the predictive performance of strategies to predict EC-MPS exposure. Given the considerable pharmacokinetic variability associated with mycophenolate therapy, limited sampling strategies may potentially help in individualizing patient dosing. However, a compromise needs to be made between the predictive performance of the strategy and its clinical feasibility. An opportunity exists to combine research efforts globally to create an open-source database for MPA (AUC, concentrations and outcomes) that can be used and prospectively evaluated for AUC target-controlled dosing of MPA in autoimmune diseases.
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Introduction
Mycophenolic acid (MPA) has been widely used for prevention of graft rejection in transplantation and is now also increasingly being used in treatment of autoimmune diseases [1] . Formulated as mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS), these prodrugs are rapidly hydrolysed to the active entity, MPA, upon oral administration [2] . Following introduction into clinical practice as a 'one-dose-fits-all' drug, MPA has been typically administered at a fixed dose without routine measurement of MPA concentrations. However, this dosing strategy may not be the optimal therapeutic option and there is increased interest in therapeutic drug monitoring (TDM) of MPA aimed at improving patient outcomes [3] [4] [5] [6] [7] [8] .
A clear association between drug exposure and effect, substantial between-subject pharmacokinetic variability and a narrow therapeutic window provide the rationale for TDM of MPA. The existence of a strong relationship between MPA exposure and treatment efficacy has been observed in studies involving patients with autoimmune disease [9] [10] [11] [12] [13] [14] [15] . These findings are in agreement with results from transplant recipients where an association between MPA exposure and the risk of acute rejection has been demonstrated [4] [5] [6] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . A correlation between MPA exposure and adverse events has been more difficult to establish in both autoimmune disease patients [11, 14, 15] and transplant recipients [4-6, 17, 19, 20, 25] . Lack of a clear-cut relationship between MPA exposure and toxicity may be due to the low incidence of some adverse events, multi-causality of adverse events including associated toxicity profiles of concomitant immunosuppressants, time elapsed between MPA measurement and adverse events, and different assays being employed for MPA quantification [7] .
Large between-subject variability has been demonstrated in the pharmacokinetics of MPA in transplant recipients with dose-normalized MPA area under the concentration-time curve from 0 to 12 h post-dose (AUC 12 ) varying more than tenfold across individuals [2, 26] . Similarly, five-to tenfold between-subject variability in MPA exposure has been reported in individuals with autoimmune diseases [1] . Little is known about the extent of within-subject variability in the pharmacokinetics of MPA in autoimmune disease patients because of the scarcity of repeated assessment in the one individual [1] . However, on the basis of data from transplant recipients, it is expected to be relatively low compared with betweensubject variability [1] . Large between-subject and likely small within-subject variability provide further compelling arguments in favour of MPA TDM.
A therapeutic window for MPA AUC 12 of 30-60 mg Á h/L has been recommended in transplantation [7] . The upper limit of this therapeutic range was defined on the basis of lack of additional efficacy rather than increased risk of toxicity. A therapeutic window for MPA AUC 12 in autoimmune disease patients is yet to be established. On the basis of data to date, lower cut-off values for MPA AUC 12 of 30, 35 and 45 mg Á h/L have been proposed for childhood-onset systemic lupus erythematosus (SLE) [9] , adult SLE [11] and lupus nephritis [15] , respectively. Within the renal transplant setting, minimum MPA trough concentration (C trough ) thresholds of C1.3 and C1.9 mg/L with cyclosporine and tacrolimus co-therapy, respectively, have been recommended, on the basis of the assumption that at least 80 % of patients with these trough concentrations attain an AUC 12 [30 mg Á h/L [3, 7] . With regard to autoimmune disease patients, MPA C trough target ranges of 0.9-3.0 mg/L [12], 1.0-5.0 mg/L [13] and 3.5-4.5 mg/L [14] have been suggested. Another study has proposed a minimum C trough threshold of 3.0 mg/L [10] . However, it is not clear whether or how C trough values in people with autoimmune disease relate to MPA exposure assessed using MPA AUC 12. If mycophenolate dose individualization through TDM is to be performed, methods for estimating MPA exposure that are both accurate and precise, and are also practical for use in the clinic, are essential. While AUC 12 is generally considered the best marker of overall drug exposure, the need to collect multiple concentration-time measurements over the full dosing interval makes this approach impractical for routine clinical use. A single-point sampling strategy, using either trough or non-trough concentrations, is relatively easy to perform but may not provide accurate estimates of full drug exposure [7, 27] . Limited sampling strategies where MPA AUC 12 is estimated from a few concentration-time points using either multiple linear regression or maximum a posteriori (MAP) Bayesian analysis provides a feasible alternative for determination of full drug exposure [28] [29] [30] . Bayesian estimators using sparse individual data have been developed at the Limoges University Hospital (Limoges, France) on the basis of original pharmacokinetic models built from a large population of adult and paediatric renal and hepatic transplant recipients and adults with lupus [31] [32] [33] [34] . The future usefulness of limited sampling strategies for estimating MPA AUC 12 in patients with autoimmune disease is dependent on their predictive performance in this setting.
Aims
This review seeks to provide an overview of all currently published data around concentration monitoring strategies for MPA in patients with autoimmune disease, and to examine the accuracy and precision of the methods reported to date using limited concentration-time points to estimate MPA AUC 12 .
Literature Search and Data Extraction
Published articles were searched using the online bibliographic databases PubMed and EMBASE without imposing any study period but limited to the English language. Databases were searched in November 2013 using the search terms 'mycophenolate mofetil', 'MMF', 'Cellcept', 'mycophenolate sodium', 'EC-MPS', 'Myfortic', 'mycophenolic acid', 'MPA', 'pharmacokinetics', 'therapeutic drug monitoring', 'population model(ling)', 'NONMEM', 'limited sampling strategies', 'multiple linear regression' and 'Bayesian forecasting'. Bibliographies of relevant articles were also reviewed manually to identify additional potentially relevant studies. 'Online early' pages of relevant journals (Pharmacological Research, British Journal of Clinical Pharmacology, Therapeutic Drug Monitoring and Clinical Pharmacokinetics) were also examined in November 2013 to identify very recent manuscripts. After removing duplicates, the titles and abstracts of potentially relevant articles were screened. Full-text versions of apparently relevant articles were subsequently retrieved and reviewed to confirm eligibility.
The following data were extracted from each study: autoimmune disease diagnosis, number of subjects, age of persons involved, mycophenolate formulation administered and dosing regimen used, as well as use of concomitant medications where stated. Blood sampling times and the assay employed for determination of MPA concentration were also documented. Correlation between MPA AUC 12 estimated by full concentration-time profiling and single concentration-time point measurements were recorded, as was the predictive performance of limited sampling strategies for estimating MPA AUC 12 . Predictive performance was evaluated by examining the bias and imprecision between the strategy-predicted AUC 12 and the estimated AUC 12 based on all data points collected. Reported mean percentage predictive error (MPPE) and root mean squared prediction error (RMSE) or mean absolute prediction error (MAPE) (defined in the calculations below) were used to assess bias and imprecision, respectively [35] .
where Pe i = prediction error = predicted value -actual value; N = number of data points. In this review, bias and imprecision [15 % were deemed unacceptable in the context of routine clinical use. [15, [36] [37] [38] .
Three studies specifically compared the association between MPA C trough and MPA AUC 12 following MMF and EC-MPS administration in autoimmune disease patients [15, 39, 40] . Of these studies, only one had a randomized cross-over design [40] . In this study, involving ten progressive immunoglobulin (Ig) A nephritis patients, a significant relationship between MPA C 12 and MPA AUC 12 was found for both formulations (MMF r 2 = 0.50; EC-MPS r 2 = 0.55). Similarly, another study conducted in SLE patients without renal manifestation revealed that there was a significant correlation between MPA C 12 and MPA AUC 12 for MMF (r 2 = 0.78, n = 21) and EC-MPS (r 2 = 0.46, n = 14) [39] . Demographic and clinical characteristics were comparable between MMF and EC-MPS groups. In contrast, one study observed a significant correlation between MPA C 0 (taken in the morning) and MPA AUC 12 following MMF administration (r 2 = 0.90, n = 12) but MPA C 0 did not provide accurate estimation of MPA AUC 12 after intake of EC-MPS (r 2 value was not stated, Table 2 Studies that examined the correlation between mycophenolic acid single concentration-time points and area under the concentration-time curve from 0 to 12 h in patients with autoimmune disease
Number of patients Dose (g/day)
between C n and AUC 12 Ref. Table 3 Studies that examined the correlation between mycophenolic acid single concentration-time points and area under the concentration-time curve from 0 to 12 h in transplant recipients
Type of transplant
between C n and AUC 12 Ref. Ref. Serum albumin (g/dL)
4.3 ± 0.7 4.6 ± 0. Creatinine clearance was estimated using 24-h creatinine clearance c Creatinine clearance was estimated using the Cockcroft-Gault formula n = 6) [15] . Comparison of demographic and clinical characteristics between formulation groups was not reported. Three studies have prospectively compared the association between MPA C trough and MPA AUC 12 values in autoimmune disease patients with that in renal allograft recipients [38, 41, 42] . Table 4 summarizes the demographics of autoimmune disease patients and renal allograft recipients. All three observed a stronger correlation in patients with autoimmune disease. Correlation between MPA C 12 and MPA AUC 12 following MMF administration was r 2 = 0.58 and r 2 = 0.30 in 16 autoimmune disease patients (10 ANCA-associated vasculitis and 6 SLE) and 16 renal transplant recipients co-treated with cyclosporine, respectively [41] . In a second study, correlation between MPA C 0 and MPA AUC 12 following MMF administration was r 2 = 0.94 in the autoimmune disease group (n = 6) compared with r 2 = 0.26 in 16 renal transplant recipients on cyclosporine co-therapy and r 2 = 0.46 in eight renal transplant recipients on tacrolimus co-therapy [42] . In a third study, involving 12 individuals with autoimmune disease (10 ANCA-associated vasculitis and 2 SLE) and 11 renal transplant recipients, correlation between MPA C 0 and MPA AUC 12 following EC-MPS administration was r 2 = 0.59 in the autoimmune disease group compared with r 2 = 0.54 in the renal transplant recipients, irrespective of the type of concomitant calcineurin inhibitor received in the latter group [38] .
Limited Sampling Strategies

Multiple Linear Regression
Two studies were identified that devised multiple linear regression equations to estimate MPA AUC 12 in patients with autoimmune disease [39, 43] . Table 5 shows the multiple linear regression equations developed using various timed concentrations and reported correlation, bias and imprecision (r 2 , MPPE and RMSE) between strategypredicted and observed MPA AUC 12 . In both studies full MPA AUC 12 was calculated using the trapezoidal method.
de Winter et al. [43] developed a limited sampling strategy for determination of MPA AUC 12 in 38 autoimmune disease patients (26 ANCA-associated vasculitis and 12 SLE) on MMF (8 % of the patients received cyclosporine co-therapy). Sampling times were a combination of one, two or three study sampling times within 4 h postdose. In order to obtain information on the extent of enterohepatic recirculation of MPA, an additional sample at 6 h post-dose was also used. This limited sampling strategy was developed in an index set of 19 patients and validated in an independent group of 19 patients. Sampling times at 0, 1 and 3 h post-dose provided the best predictive Inclusion of the extra sample at 6 h post-dose resulted in a further improvement in imprecision to 17.3 % (95 % CI 9.0, 22.7) but this additional sample would be clinically less convenient for routine use.
Djabarouti et al. [39] determined a limited sampling strategy to predict MPA AUC 12 in 14 SLE patients without renal manifestations on EC-MPS. Sampling times were selected by testing all combinations of study sampling times. Only equations with an acceptable r 2 ([0.75) and mean bias and imprecision \15 % were validated, using a resampling technique based on the 'jackknife' (or circular permutation) method. The limited sampling strategies using two and three sampling times within 3 h post-dose produced biased and imprecise predictions. The recommended sampling times were at 2, 3, 4 and 12 h post-dose with bias and imprecision of 6.5 % (95 % CI -2.5, 14.8) and 10.2 % (95 % CI 2.5, 15.0), respectively. Bland-Altman analysis showed adequate agreement between the observed MPA AUC 12 and that estimated using the fourpoint limited sampling strategy as all values fell within mean ± 2 standard deviations. Unfortunately, the predictive performance of this equation was poor in patients whose time to reach MPA maximum concentration (t max ) was [4 h (4 out of the 14 patients).
Maximum A Posteriori Bayesian Analyses
Three studies were identified that used MAP Bayesian estimation to predict MPA AUC 12 [34, 43, 44] . Table 6 provides the reported correlation, bias and imprecision (r 2 , MPPE and RMSE) of sampling time combinations between strategy-predicted and measured MPA AUC 12. In all studies full MPA AUC 12 was calculated using the trapezoidal method. Population pharmacokinetic models were developed initially for estimation of typical pharmacokinetic parameters, determination of the extent of betweensubject variability and characterization of the influence of covariates on the pharmacokinetics of MPA [1] .
Apart from multiple linear regression analysis, de Winter et al. [43] also developed a limited sampling strategy for determination of MPA AUC 12 in 38 autoimmune disease patients (26 ANCA-associated vasculitis and 12 SLE) on MMF (8 % of the patients received cyclosporine co-therapy). Non-linear mixed-effects modelling techniques were used. The population pharmacokinetic model was developed in an index set of 19 patients and parameters obtained were used in MAP Bayesian analysis to estimate MPA AUC 12 on the basis of a limited number of sampling times, selected as combinations of one, two or three times within 4 h post-dose. An additional sample at 6 h post-dose was included to obtain information on enterohepatic recirculation of MPA. Strategy-predicted performance was evaluated in an independent validation set of 19 patients. Similar to multiple regression analysis, sampling times at 0, 1 and 3 h post-dose provided the best predictive performance with bias of -5. Sam and Joy [44] developed a limited sampling strategy for predicting MPA AUC 12 in 39 patients with glomerulonephritis secondary to ANCA-associated vasculitis and SLE on MMF (8 % of the patients received cyclosporine co-therapy) using non-linear mixed-effects modelling techniques. Final population pharmacokinetic estimates and a combination of three blood samples and one urine sample collected within 6 h post-dose were utilized in MAP Bayesian analysis for estimation of MPA AUC 12 . The limited sampling strategy was validated using a circular permutation method. Nine different combinations of three time points were examined with bias and imprecision ranging from -5.8 to -9.0 and 31.7 to 34.3 %, respectively. As the bias was \15 % for all of these combinations, sampling time points at 0, 1 and 3 h post-dose were selected as the most appropriate sampling schedule since this combination provided the least imprecision (31.7 %).
Zahr et al. [34] established a limited sampling strategy to estimate MPA AUC 12 using pharmacokinetic profiles from 20 SLE patients on MMF without cyclosporine co-therapy. Contrary to the previous studies, an iterative two-stage Bayesian procedure was conducted for estimation of MPA population pharmacokinetic parameters and calculation of AUC 12 . A combination of a maximum three sampling times within 3 h post-dose were selected as sampling times for investigation on the basis of good compromise between predictive performance and clinical utility. Validation of the limited sampling strategies by a 'jackknife' (circular permutation) method was performed. MPA AUC 12 was best estimated using sampling times at 0.33, 2 and 3 h post-dose. Under this strategy bias was -4.1 % (95 % CI -69.3, 31.8); however, imprecision was not reported. Bland-Altman analysis showed good agreement between observed and predicted MPA AUC 12 and an average error of 2.11 mg h/L.
Discussion
Several studies characterizing TDM strategies in predicting MPA AUC 12 in people with autoimmune diseases have been published. Correlations between MPA C trough (both C 0 and C 12 ) and MPA AUC 12 ranged from 0.15 to 0.94 and from 0.13 to 0.68 following MMF and EC-MPS administration, respectively. Interestingly, a higher association (r 2 = 0.90-0.94) was observed in lupus nephritis patients receiving MMF treatment without cyclosporine co-therapy; however, these findings may be unreliable because of the small number of patients studied [15, 42] . A significant proportion of between-occasion variability in MPA C trough values is likely caused by day-to-day fluctuation in this drug's enterohepatic recirculation, making C trough an unlikely candidate for accurate prediction of MPA AUC 12 .
In studies that directly compared correlations (r 2 ) using MMF and EC-MPS, MMF (r 2 = 0.15-0.90) demonstrated a better association between MPA C trough (both C 0 and C 12 ) and MPA AUC 12 than EC-MPS (r 2 = 0.13-0.55) [15, 39, 40] . This finding is consistent with studies in renal transplant recipients where correlation was relatively higher following ingestion of MMF (r 2 = 0.45-0.47) than EC-MPS (r 2 = 0.02-0.16) [45, 46] . Aberrant and variable release of MPA from the enteric-coated formulation as well as day-to-day fluctuation in this drug's enterohepatic recirculation are likely to explain this finding [45] [46] [47] [48] [49] [50] . As with MMF, C trough values are unlikely to be helpful in guiding dosing of EC-MPS.
A stronger correlation between MPA C trough and MPA AUC 12 following MMF [41, 42] and EC-MPS [38] administration has been described in autoimmune disease patients compared with renal allograft recipients. Differences in demographic profiles, with autoimmune disease patients having significantly better renal function than renal allograft recipients in two of the three studies, may contribute to this discrepancy [38, 42] . Although renal function in autoimmune disease patients was not significantly different from that of kidney transplant recipients in the third study, there was a trend towards better renal function in the former group [41] . In the third study, renal allograft recipients were significantly heavier than autoimmune disease patients [41] . While some studies did not find a correlation between bodyweight and MPA pharmacokinetics [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] , other studies demonstrated that MPA clearance [65] [66] [67] [68] and central volume of distribution [68, 69] were affected by bodyweight. This suggests that bodyweight may be a factor in this third study. Prednisolone dose was found to be significantly higher in the autoimmune disease group in one study [42] , and this may increase MPA clearance [61, 70] . However, its impact on MPA disposition is not really crucial as compared with the effect of better renal function in this group. Renal transplant recipients also have been prescribed concomitant different calcineurin inhibitors, which may influence the MPA C trough -MPA AUC correlation. Inhibition of multidrug resistance-associated protein-2 (MRP-2, also known as ABCC2) by cyclosporine causes interruption of MPA enterohepatic recirculation and subsequently lowers MPA exposure, which might have been anticipated to lead to more predictable AUC [71] [72] [73] [74] [75] [76] [77] . Unexpectedly, one study directly comparing the MPA C trough -MPA AUC 12 correlation in lupus nephritis patients and renal allograft recipients receiving either concomitant cyclosporine or tacrolimus found that the correlation in kidney transplant recipients co-treated with cyclosporine was worse than that in renal allograft recipients who received tacrolimus [42] .
Interestingly, MPA C 12 (evening) values appear to correlate better with MPA AUC 12 than C 0 (morning) values following MMF [39, 40] and EC-MPS administration [37, 39, 40] . This might be attributed to circadian variation in the pharmacokinetics of MPA. Studies in renal allograft recipients have shown that MPA AUC 12 and maximum concentration of MPA (C max ) are higher, t max is shorter and apparent oral clearance (CL/F) is lower following a morning dose compared with an evening dose [78, 79] . The interval between mycophenolate administration and food consumption and a potential interaction between MPA and the morning corticosteroid dose may contribute to this [78, 79] . As breakfast was served within 2 h of MMF or EC-MPS administration, food can stimulate gall bladder emptying with release of MPA metabolite, mycophenolic acid glucuronide (MPAG) with the bile followed by MPAG deglucuronidation and MPA reabsorption [37, 39, 40] . Induction of MPA glucuronidation by corticosteroids resulting in low MPA exposure has been reported in one study [70] . In addition, positive correlation with corticosteroid dosage and MPA CL/F has been identified on univariate analysis but not on multivariate analysis in a population pharmacokinetic meta-analysis of 488 renal allograft recipients [61] .
The best correlations reported between single concentration-time points and observed MPA AUC 12 were concentrations at 0.5 h (C 0.5 ) [15] and 2 h (C 2 ) [36] following MMF intake (r 2 = 0.78-0.92). In contrast, C 2 [38] and concentration at 6 h (C 6 ) [37] post-dose were demonstrated as the best predictors of MPA AUC 12 following EC-MPS intake (r 2 = 0.73-0.92). Unfortunately, the authors did not report predictive performance of these time points. Studies in solid organ transplant patients reported that different single time points were best correlated with MPA AUC 12 following MMF (0.66, 1, 1.5, 3, 4, 6, 8, 9 and 10 h postdose) (r 2 = 0.53-0.91) [28, 29, [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] and EC-MPS (2, 4, 8 and 10 h post-dose) (r 2 = 0.30-0.77) ( [94] [95] [96] administration. Bias ranged from -28.5 to 15.9 %, which exceeded the limitation of ±15 % [28, 85, 87, [90] [91] [92] . These time points were able to predict within ±15 to 20 % of the corresponding full MPA AUC 12 in 14-55 % of patients receiving MMF treatment [28, 85, 87, [90] [91] [92] . On the basis of these data, no single concentration-time point is likely to be useful for mycophenolate TDM.
In view of the low correlations between single time points and MPA exposure, limited sampling strategies have been developed as an alternative for estimation of MPA AUC 12 . Multiple linear regression analysis uses an equation derived from stepwise regression analysis based on concentrations measured at pre-defined times after dosing. Such equations are relatively easy to use but have a heavy reliance on exact sampling times, with deviations potentially compromising predictive utility for future dosing [7, 27, 30, 97] . MAP Bayesian estimation uses information from a population pharmacokinetic model of MPA and sparse concentration-time points from an individual to obtain the most likely pharmacokinetic parameter estimates for that specific person [97, 98] . This method offers superior flexibility in timing of blood sampling and improved predictive performance with the addition of patient demographic, clinical characteristics and pharmacokinetic data into the model [7, 27, 30, 97] . However, clinical application may be more limited as the more complex calculations require specialist software with trained users and is dependent on the existence of an appropriate pharmacokinetic model [7, 27, 30, 97] . In 2005, the Limoges University Hospital (Limoges, France) launched a free website service for MMF dosage estimation based on Bayesian forecasting (https://pharmaco.chulimoges.fr/). This ImmunoSuppressant Bayesian dose Adjustment (IBSA) program offers great opportunities for clinicians to individualize and optimize MMF therapy in adults with lupus.
In one of the studies developing a limited sampling strategy using multiple linear regression [38] a three-sample strategy (0, 1 and 3 h after MMF dosing) gave low bias (0.8 %) but still had imprecision above 15 %. An extra sample at 6 h post-dose reduced model imprecision (from 23 to 17 %), giving more precise estimation in those patients with MPA enterohepatic recirculation. These findings were consistent with those reported in transplant recipients [29, 80, 81, 84-86, 88, 91, 92, 99, 100] . Despite feasibility in clinical practice, taking all time points within 4 h post-dose is unable to fully characterize the pharmacokinetics of MPA, because of the presence of enterohepatic recirculation [29, 80, 81, 84, 86, 91, 92, 99, 100] . Another study, using EC-MPS, [39] also showed that limited sampling strategies using two or three samples obtained within 3 h post-dose poorly predict MPA AUC 12 . These findings were also in agreement with results in transplant recipients [96] . High variability in drug absorption, t max and C 0 owing to its enteric coating contributed to poor predictive performance of the strategies [96] . This makes a reliable estimation of MPA AUC 12 drawn within 3 h of EC-MPS administration challenging. Underestimation of MPA exposure is reported, especially if t max falls outside the sampling time period [92, 96, 100] .
Similar to MMF, inclusion of samples at later time points that capture the t max and enterohepatic recirculation resulted in better predictive performance after EC-MPS administration [39, 94, 95, 101, 102] . In light of the suppression of MPA enterohepatic recirculation by cyclosporine, the establishment of limited sampling strategies might be possible as time points beyond 6 h following MMF [28, 56, 87, 89, 91, 93, 100, 103] and EC-MPS [95, 102] may not be essential in people with autoimmune diseases receiving concomitant cyclosporine. On the contrary, enterohepatic recirculation of MPA is not inhibited by concomitant use of tacrolimus. Limited sampling strategies incorporating only early concentration-time points may estimate MPA exposure inaccurately. Limited sampling strategies that included time points in the latter half of the dosing interval provided better predictive performance compared with ones that did not following MMF [29, 80, 85, 86, 88, 104] and EC-MPS [105, 106] intake. According to the American College of Rheumatology (ACR) guideline, the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR-ERA-EDTA) recommendations, the Kidney Disease Improving Global Outcomes (KDIGO) guideline and the Asian Lupus Nephritis Network (ALNN) guidelines, multi-target immunosuppression (combination of mycophenolate, corticosteroid and calcineurin inhibitor) might be considered as an alternative treatment option in lupus nephritis patients who are intolerant of or unresponsive to conventional therapies, so these combined regimens are used, albeit less frequently in autoimmune disease patients than in renal transplant recipients [107] [108] [109] [110] .
Determination of MPA AUC 12 using MAP Bayesian estimation in autoimmune disease patients following MMF administration has been reported [34, 43, 44] . Generally, bias was \10 % but imprecision ranged from 8 to 34 %. Ideally, the type of calcineurin inhibitor used needs to be considered in the model development (8 % of patients received concomitant cyclosporine in the reported studies). As pre-dose cyclosporine concentration influences MPA clearance and consequently MPA exposure by interrupting MRP-2-mediated enterohepatic recirculation [61, 111] , it should be incorporated for computation of Bayesian algorithms and individualization of MPA dosage [98] . There is a compromise in selecting sampling times that have the best predictive performance and that are clinically practical. In these studies, combinations of a maximum of three samples within 3 h [34] , 4 h [43] or 6 h [44] post-dose were used. One of these studies had included one urine sample in addition to three plasma samples within 6 h of MMF intake for Bayesian estimation of MPA AUC 12 [44] . The contribution of the urine sample in Bayesian estimation is unclear as this parameter was not included in the algorithms. MAP Bayesian estimation also depends upon the reliability of the population models. One of the three studies used a 1-compartment model with first-order elimination convoluted with a triple c distribution to fit MPA concentration-time data [34] . The third peak corresponded to enterohepatic recycling of MPAG and subsequent re-conversion to MPA. The remaining studies incorporated a gallbladder compartment in a 2-compartment model, reflecting possible recirculation of MPA [43, 44] . None of these models sampled on more than one occasion and included intra-individual variability in their model. When evidence of enterohepatic recycling exists in the concentration-time profile of MPA, it is important to attempt to include an enterohepatic recycling model, to aid in explaining high variability [112] . Exclusion of this component may result in underestimation of clearance as well as exposure. Ideally, models need to include not only patient demographics but also other physiological factors, specifically those related to the biliary excretion of MPAG and to the overall enterohepatic process [112] . In the future as our understanding of the pharmacokinetics of MPA grows it will also likely be useful to model the influence of genetic differences and ontogeny in transporters and enzymes as factors potentially influencing overall drug exposure [112] . Improvement of algorithms by refinement of Bayesian enterohepatic recirculation models would facilitate individualization of MPA dosing. All three models [34, 43, 44] employed in Bayesian estimation in this review were developed in fewer than 50 subjects and are unlikely to fully characterize mycophenolate pharmacokinetics in different clinical scenarios.
During testing of any limited sampling strategy the reference AUCs used for comparison with the predicted AUCs must be determined by a reliable method. In all of the limited sampling studies, the reference AUC was approximated by the trapezoidal rule [34, 39, 43, 44] , from summation of integrations between consecutive concentration-time points. Approximation to true concentrations is dependent on the length of time between measurements. Greater frequency of sampling times improves the accuracy of AUC approximation. In these studies, 9-11 samples were obtained over 12 h to define the concentration-time profile but the number of sampling points around the secondary peak was limited, which could lead to under-estimation of the true AUC. As enterohepatic recirculation contributes up to 40 % (range 10-60 %) of total MPA exposure [2] , extensive sampling at these time points should improve the accuracy of the AUC approximation.
In all of these studies, sampling times were determined by comparing the predictive performance of all relevant combinations of sampling times [34, 39, 43, 44] . As the possible combinations are limited by the sampling times of the study design, selected sampling times cannot be considered as truly ideal [97] . Another method of determining sampling times is by D-optimality, based on the premise that there are some sampling times containing more information about pharmacokinetic parameters than others [97] . This method has yet to be tested with regard to limited sampling development in autoimmune disease patients receiving mycophenolate but offers great potential in model-based dose optimization.
Bias and precision analyses provide information on the systematic error (tendency of limited sampling strategies to consistently under-or overestimate AUC) and absolute error (magnitude of variation in predicting AUC), respectively, in contrast to correlation analysis, which only provides a measure of strength of association [35, 113] . It should be noted, however, that metrics such as the MPPE, RMSE, MAPE and r 2 are insufficient on their own to fully evaluate any LSS. MPPE, RMSE and MAPE are average indices that do not fully take into account outliers and high r 2 values can still be compatible with predictive error values non-acceptable for the safety of certain patient (outliers). As well as examining mean values, it is useful to consider the range associated with the prediction error and to give the percentage of patients exhibiting a relative bias [20 and \20 %, as was performed in one study [34] . One study did not report the imprecision of the limited sampling strategies [34] whereas one study used MAPE as a measure of imprecision [39] . Ideally, graphical analyses such as Bland-Altman plots should also be used to evaluate the degree of agreement between predicted and measured AUC [113] . Only two studies examined in this review included Bland-Altman analysis in their assessment [34, 39] . Because of the small number of subjects, limited sampling strategies have been evaluated using internal validation, either through data splitting (without stating whether patients were randomized or stratified into different groups) [43] or using a resampling technique [34, 39, 44] . External validation is a more stringent, generalizable method for evaluation, performed in an independent new dataset. Internal validation may be acceptable if the strategy is being evaluated as a descriptive tool only, but is generally not acceptable for the strategy to become subsequently used for dosage prediction. More robust external validation would be required.
As concomitant immunosuppressant usage has been shown to influence MPA pharmacokinetics, the generalizability of these strategies is limited to patient populations taking the same medication regimes [114] [115] [116] [117] [118] [119] . Furthermore, limited sampling strategies developed in patients receiving MMF are not applicable to patients treated with EC-MPS, because of different and more variable pharmacokinetic properties [45] [46] [47] [48] [49] [50] . All studies included in this review examined the Cellcept Ò and Myfortic Ò brands of MMF and EC-MPS, respectively. As the patent for MMF has already expired in some countries and generic formulations of MMF become available, limited sampling strategies may also need to be developed for new generic brands of mycophenolate. The pharmacokinetic profiles may differ between the two products, as products may not necessarily be bioequivalent, and limited sampling strategies developed in one product may not perform well when applied to another product [7, 120] . If the generics are assessed by regulatory agencies as bioequivalent, then limited sampling strategies should be transferable [121] . Moreover, individuals with chronic plaque psoriasis and rheumatoid arthritis may have different MPA pharmacokinetic profiles from SLE and ANCA-associated vasculitis patients as patient renal function is likely to be more affected in these latter patients [1] . This warrants development of population pharmacokinetic models and limited sampling strategies specific for these populations. Given that the MPA concentrations measured by the enzymemultiplied immunoassay technique (EMIT) may be 15-20 % higher than those measured by high-performance liquid chromatography (HPLC), the limited sampling strategies developed using different analytical techniques may also not be interchangeable [122] [123] [124] [125] .
Further investigation is warranted in several areas including (1) establishment of MPA exposure targets across different autoimmune disease populations and identification of an upper exposure limit; (2) development of optimal MPA monitoring strategies and determination of the best methodologies; (3) external validation of MPA AUC prediction and monitoring strategies; (4) quantitation of the clinical benefits of monitoring MPA exposure; and (5) individualization of mycophenolate dosing through TDM. There does appear to be an opportunity here, with many groups working on the topic, to combine efforts globally to create an open-source database for MPA that can be used and prospectively evaluated for AUC targetcontrolled dosing, similar to that created as the Open TCI Initiative by the World Society of Intravenous Anesthesia (http://opentci.org/doku.php).
Conclusions
There has been increased interest in individualization of mycophenolate dosing for improvement of patient outcomes. This can be achieved by targeting MPA exposure. Limited research has been conducted to investigate single concentration-time points and limited sampling strategies for TDM of MPA in autoimmune disease. Most of the reports have focused on MMF in patients with SLE and ANCA-associated vasculitis, with research gaps identified for evaluation of strategies in predicting MPA exposure in other autoimmune disease populations and with EC-MPS. Correlations between single concentration-time points and MPA AUC 12 following MMF administration ranged from 0.15 to 0.94. For multiple linear regression method and MAP Bayesian estimation analysis, optimal sampling times at pre-dose and at 1 and 3 h post-dose upon MMF intake provided better predictive performance than single time points. Although a multiple linear regression method was superior in term of the mean bias compared with MAP Bayesian estimation, the latter is likely preferable as a result of superior flexibility as to when samples can be taken. For the studies that have been performed with EC-MPS, poor correlations between single concentrationtime points and MPA AUC 12 were found because of variable pharmacokinetic profiles. Estimation of MPA AUC 12 based on multiple linear regression analysis of samples drawn within 3 h post-dose resulted in biased and imprecise predictions, especially in patients whose t max was longer than 4 h. Incorporation of later time points that captured t max and enterohepatic recirculation improved the predictive performance; however, sampling at these times could prove clinically impractical. MAP Bayesian analysis methods for prediction of MPA exposure following EC-MPS intake in people with autoimmune disorders are yet to be developed. Given the considerable pharmacokinetic variability associated with mycophenolate therapy, limited sampling strategies may potentially help in individualizing patient dosing. However, a compromise needs to be made between the predictive performance of the strategy and its clinical feasibility. An opportunity exists to combine research efforts globally to create an open-source database for MPA (AUC, concentrations and outcomes) that can be used and prospectively evaluated for AUC target-controlled dosing of MPA in autoimmune diseases.
